Monday, June 22, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 518 of 1,261
  1. US 10201282

    Genetically encoded infrared fluorescent protease reporters

    The Regents of the University of California · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  2. US 10202595

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  3. US 10202578

    Chicken cells for improved virus production

    The Pirbright Institute · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  4. US 10202452

    CD3 binding polypeptides

    Aptevo Research and Development LLC · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  5. US 10202584

    Red-shifted luciferase-luciferin pairs for enhanced bioluminescence

    The Regents of the University of California · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  6. US 10202428

    Compositions and methods for the delivery of oxygen

    The Regents of the University of California · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  7. US 10202412

    β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections

    Atea Pharmaceuticals, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  8. US 10202399

    Dihydroxy aromatic heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  9. US 10202376

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  10. US 10202631

    Multi-tiered, high through-put screen for compounds effective against bacterial biofilm compounds effective for inhibiting and eradicating bacterial biofilm

    United States of America as represented by the Secretary of the Air Force · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  11. US 10202340

    Glucosylceramide synthase inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  12. US 10202348

    Compositions and methods of treating retinal disease

    Aldeyra Therapeutics, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  13. US 10201613

    Method of creating hydrogels through oxime bond formation

    The Regents of the University of California · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  14. US 10201603

    Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

    The Regents of the University of California · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  15. US 10202366

    Methods of promoting wound healing using CRM1 inhibitors

    Karyopharm Therapeutics Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  16. US 10196377

    Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  17. US 10195291

    Compositions and methods for the manufacture of lipid nanoparticles

    Alnylam Pharmaceuticals, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  18. US 10195612

    Small particle compositions and associated methods

    Primet Precision Materials, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  19. US 10195222

    Acyclic nucleoside phosphonate diesters

    The Regents of the University of California · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  20. US 10195236

    Use of gram negative species to treat atopic dermatitis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  21. US 10195278

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  22. US 10195202

    Methods for modulating the amount of RNA transcripts

    PTC THERAPEUTICS, INC. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  23. US 10195214

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  24. US 10195165

    Methods of treating Prader-Willi syndrome

    OVID THERAPEUTICS INC. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.